Navigation Links
Simbionix Increases Product Offerings for OB/GYN Physicians
Date:3/11/2009

CLEVELAND and ZURICH, Switzerland, March 11 /PRNewswire/ -- Simbionix, the world's leading developer of medical simulation systems, and VirtaMed, a Swiss medical engineering company, announced today a global collaboration agreement. Simbionix will exclusively distribute, market, and provide service for the VirtaMed HystSim, an advanced virtual reality hysteroscopy simulator.

Simbionix already offers a wide spectrum of simulators for minimal invasive surgery. "This new agreement further expands our product offering," says Simbionix CEO Gary Zamler. "The addition of the HystSim simulator, along with our recently launched laparoscopic surgery module for gynecology, shows how seriously Simbionix is investing in women's healthcare issues".

Simbionix' President and founder, Mr. Ran Bronstein, adds: "Our simulation technology is definitely a revolution in the world of medical training and assessment. We are happy to be working together with VirtaMed, a company as committed to technology and simulation quality as we are. Simbionix will keep increasing its product offering to the medical community and bring quality and service to its customers and partners."

"VirtaMed is thrilled to be working together with Simbionix, the market leader in surgical simulation," adds VirtaMed CEO Stefan Tuchschmid. "Simbionix is a partner that will ensure the HystSim simulator is available globally. We truly appreciate Simbionix' commitment to provide the best possible training for surgeons in every field."

VirtaMed HystSim(TM) will be officially launched at the next ACOG (American College of Obstetricians and Gynecologists) annual clinical meeting held in Chicago on May 2nd.

Further information and product demonstrations are available from your local Simbionix sales representative and at http://www.simbionix.com.

About VirtaMed

VirtaMed is a Swiss based company with an interdisciplinary background in medicine and engineering. The HystSim(TM) system is the first VirtaMed product and provides instructional teaching and training of diagnostic and therapeutic hysteroscopy. VirtaMed's mission is to develop state-of-the-art training tools for endoscopic surgery of highest possible realism, all with the ultimate goal to improve the quality of patient care. Additional company information can be found at http://www.virtamed.com.

About Simbionix

Simbionix is a global leader in medical simulation technology. Simbionix mission is to provide state of the art, computer-assisted metrics-based surgical simulation systems, and set the standard for minimally invasive surgical training and performance.

Simbionix products provide medical experts with hands-on training in a comprehensive array of MIS procedures, including; GI Endoscopy, Endourology, percutaneous access, advanced laparoscopic procedures and Endovascular procedures. Visit http://www.simbionix.com

    Contact:
    Inbal Mazor
    VP Marketing
    Simbionix
    inbal@simbionix.com
    Tel: +972-8-9211177



'/>"/>
SOURCE Simbionix Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Glen C. Williams Joins eLearning Sales Team for Simbionix, Heading up Chicago Office
2. New Colorectal Module From Simbionix Advances Laparoscopic Cancer Treatment
3. William E. Lewandowski to Lead Simbionix US Marketing Team in Simbionixs Strategic Expansion in the US Market
4. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
5. Simbionix Launches Innovative Patient-Specific Simulation
6. Simbionix Releases Powerful New Learning Management System With Enhanced True Assessment System(TM)
7. Simbionix Takes Non-Invasive GYN Surgical Training to the Next Level
8. 2007 a "Record Year" for Successful Validation Studies of Simbionix Simulators
9. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
10. Despite Economic Woes, Physician Compensation Increases
11. Gerresheimer Substantially Increases Quarterly Operating Profit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay for nicotine ... 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional needs of ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... today announced their digital pathology technology has the potential to eliminate subjectivity in ... centers in The Netherlands as part of the 2017 ISBI CAMELYON Digital ...
(Date:4/27/2017)... ... April 27, 2017 , ... Arrowhead Publishers is pleased to ... coming to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, ... advances in the treatment of various types of pain. There are also extended ...
(Date:4/27/2017)... Orleans, La. (PRWEB) , ... ... ... Monitoring Technologies today announced a comprehensive rebrand and a name change to ... for the industrial and laboratory monitoring of polymer and biopharmaceutical manufacturing processes ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):